Research & Development

Arcellx and Gilead's New Therapy Shows Promise for Multiple Myeloma
Research & Development Arcellx and Gilead's New Therapy Shows Promise for Multiple Myeloma

The ongoing search for better and safer treatments for multiple myeloma, a type of blood cancer, has taken a significant step forward with the development of a new cell therapy by Arcellx and Gilead Sciences. The pioneering approach demonstrated a substantial reduction or total eradication of

Naobios and Sumagen Achieve Milestone in HIV-1 Vaccine Development
Research & Development Naobios and Sumagen Achieve Milestone in HIV-1 Vaccine Development

Naobios and Sumagen Canada Inc., a subsidiary of CreoSG Co., Ltd, have achieved a critical milestone in the development of Sumagen’s HIV-1 vaccine candidate, SAV001. This genetically modified, whole-killed HIV vaccine has shown both tolerance and safety in phase I trials, marking a significant step

GC Biopharma and Novelty Nobility Partner to Innovate GA Treatment
Research & Development GC Biopharma and Novelty Nobility Partner to Innovate GA Treatment

GC Biopharma and Novelty Nobility have announced a promising partnership aimed at developing a novel treatment for geographic atrophy (GA), a severe form of dry age-related macular degeneration (AMD). This condition leads to retinal damage and eventual blindness, making it a significant health

Pluri and Bar-Ilan Partner to Innovate Solid Tumor Cell Therapies
Research & Development Pluri and Bar-Ilan Partner to Innovate Solid Tumor Cell Therapies

Pluri Inc., a forward-thinking biotechnology firm, has recently announced a groundbreaking collaborative project with Bar-Ilan University’s Research and Development Company (BIRAD). This innovative endeavor aims to develop cutting-edge allogeneic cell therapies specifically targeting solid tumors, a

Will Jade Biosciences' Reverse Merger with Aerovate Boost JADE-001?
Research & Development Will Jade Biosciences' Reverse Merger with Aerovate Boost JADE-001?

Jade Biosciences, a burgeoning developer specializing in immune disease drugs, has set its sights on accelerating its market presence through a reverse merger with Aerovate Therapeutics. This strategic consolidation will enable Jade to promptly enter the public market under the Nasdaq ticker

Neurogene Secures $200 Million Funding Ahead of Key Rett Syndrome Data
Research & Development Neurogene Secures $200 Million Funding Ahead of Key Rett Syndrome Data

Neurogene, a trailblazer in the gene therapy field concentrating on rare neurological diseases, has successfully clinched $200 million through a private funding deal designed to extend its financial runway until late 2027. This financing structure, recognized as a PIPE financing (Private Investment

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later